<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111116">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02121665</url>
  </required_header>
  <id_info>
    <org_study_id>PLOZ/PG/PERIO/2013</org_study_id>
    <nct_id>NCT02121665</nct_id>
  </id_info>
  <brief_title>Efficacy of a Probiotic Lozenges in Chronic Periodontitis Patients.</brief_title>
  <official_title>Effect of Probiotic Lozenges as an Adjunct to Non Surgical Periodontal Therapy in Chronic Periodontitis Patients: A Randomized Double Blind Placebo Controlled Clinical and Biochemical Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CD Pharma India Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Government Dental College and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CD Pharma India Pvt. Ltd.</source>
  <oversight_info>
    <authority>India: Indian Council of Medical Research</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Periodontal disease is an infectious disease resulting in inflammation within supporting
      tissues of the teeth, progressive attachment loss, and bone loss. Epidemiological studies
      reveal that about 10% of the adult population suffer from severe periodontitis.It comprises
      of two distinct but interconnected etiologic components: the periodontopathic bacteria
      adjacent to the periodontal tissues, and the host-mediated connective tissue-destructive
      responses to the causative bacteria and their metabolic products. In the arena of
      periodontics, the probiotics pose a great potential of plaque modification, halitosis
      management, altering anaerobic bacteria colonization, improvement of pocket depth, and
      clinical attachment gain.

      Aim of the study is to analyze the beneficial effect of probiotic lozenges as an adjunct to
      Scaling and Root Planing, on clinical and biochemical parameters.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Improvement in Periodontal Clinical indices</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improvement in periodontal clinical indices, namely, Gingival Index (GI), Plaque Index (PI), Probing Pocket Depth (PPD) and Clinical attachment Loss (CAL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in biochemical indices</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in level of inflammatory markers namely PGE2, IL-1beta, TNF-alpha, receptor activator of nuclear factor kappa B ligand (RANKL), Osteoprotegerin (OPG), MMP-9 and MMP-13 in saliva sample</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Periodontitis</condition>
  <arm_group>
    <arm_group_label>Probiotic (Inersan) Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inersan Lozenges (4 Lozenges per day; 1 lozenge in morning,1 lozenge in the afternoon and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Lozenges (4 Lozenges per day; 1 lozenge in morning,1 lozenge in the afternoon and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probiotic (Inersan)</intervention_name>
    <arm_group_label>Probiotic (Inersan) Arm</arm_group_label>
    <other_name>Each Inersan lozenge contains not less than 1 billion CFU of Lactobacillus brevis CD2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Arm</arm_group_label>
    <other_name>Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject of both sexes

          -  Age group of 25-65 years

          -  Subjects with generalized moderate to severe chronic periodontitis

          -  Signed informed Consent

        Exclusion Criteria:

          -  Any known history of systemic diseases

          -  Patients already on anti-inflammatory drugs or antibiotics

          -  Patients allergic to any material used in the study

          -  Pregnant and lactating women

          -  Periodontal therapy in past 6 months

          -  Current smoker or smoker in the past
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rohan Sethi, BDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Government Dental College &amp; Hospital, Aurangabad</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rohan Sethi, BDS</last_name>
    <phone>+91-9158540560</phone>
    <email>rohansethi8@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maya S. Indurkar, BDS, MDS</last_name>
    <phone>+91-9823182694</phone>
    <email>mayaindurkar@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Periodontics, Government Dental College &amp; Hospital</name>
      <address>
        <city>Aurangabad</city>
        <state>Maharashtra</state>
        <zip>415570</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rohan Sethi, BDS</last_name>
      <phone>+91-9158540560</phone>
      <email>rohansethi8@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 22, 2014</lastchanged_date>
  <firstreceived_date>April 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Chronic Periodontitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
